Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00005650-197406000-00005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Balance in children with chronic kidney disease: the relationship between skeletal muscle mass index, fatigue, and physical function.
Pediatr Nephrol
December 2024
Department of Physical Medicine and Rehabilitation, Medical Faculty, Ondokuz Mayis University, Samsun, Turkey.
Background: The study evaluated the relationship between balance function and skeletal muscle mass index (ASMI), physical function, and fatigue in children with chronic kidney disease (CKD).
Methods: A cross-sectional study of 83 children with CKD (stages 1-4, dialysis, transplant) and 71 healthy controls was conducted. Functional performance tests, including gait speed, 6-min walk distance (6MWD), five-repetition sit-to-stand (5RST), and timed up-and-go (TUG) tests, were administered.
Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study.
Can J Kidney Health Dis
December 2022
BC Renal, Vancouver, Canada.
Background: The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) and dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trials have demonstrated significant kidney benefits with sodium-glucose cotransporter-2 (SGLT2) inhibitors. SGLT2 inhibitors are now standard of care for patients with diabetic kidney disease and have also been shown to be effective in those with albuminuric CKD with or without diabetes.
Objective: We sought to determine how many patients in nephrology care in British Columbia, Canada, would have been eligible for those trials, to compare rates of outcomes, and to estimate cost avoidance arising from widespread use of SGLT2 inhibitors in this cohort.
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
JAMA
May 2022
The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Article Synopsis
- The study aimed to determine the effectiveness of methylprednisolone, a glucocorticoid, in preventing kidney function decline in patients with IgA nephropathy who are at high risk for such decline.
- Conducted as a double-blind, randomized clinical trial with 503 participants across multiple countries, the results indicated that those receiving methylprednisolone had a significantly lower rate of serious kidney outcomes compared to those on placebo.
- After 4.2 years of follow-up, the primary composite outcome occurred in 28.8% of the methylprednisolone group versus 43.1% of the placebo group, showcasing methylprednisolone's potential benefits for patients with this kidney condition.
The Development and Use of an EHR-Linked Database for Glomerular Disease Research and Quality Initiatives.
Glomerular Dis
October 2021
Division of Nephrology, Department of Pediatrics and Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan, USA.
Background And Objective: The use of electronic health record (EHR) data can facilitate efficient research and quality initiatives. The imprecision of ICD-10 codes for kidney diagnoses has been an obstacle to discrete data-defined diagnoses in the EHR. This manuscript describes the Kidney Research Network (KRN) registry and database that provide an example of a prospective, real-world data glomerular disease registry for research and quality initiatives.
View Article and Find Full Text PDFSodium-glucose linked transporter-2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk.
Diabetes Obes Metab
July 2020
Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Nottingham, UK.
Data from three completed cardiovascular outcome trials (CVOTs), EMPA-REG OUTCOME, CANVAS Program and DECLARE-TIMI 58, add to the evidence supporting the potential renoprotective effects of sodium-glucose linked transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes. Despite recommendations in recent guidelines, it is difficult to support a view that definitive evidence for renoprotection exists from these SGLT2 inhibitor CVOT results. To date, the only dedicated trial to report definitive data on the renal impact of SGLT2 inhibition is CREDENCE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!